ClinicalTrials.gg
CompletedNCT04982874Updated Nov 2, 2023Results posted

Bioequivalence Study of Furosemide 40 mg Tablet in 24 Indonesian Healthy Volunteers

An interventional study of Furosemide 40 mg and Lasix® 40 mg Tablet in Drug Use, sponsored by PT. Kimia Farma (Persero) Tbk. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-02.

Sponsored by PT. Kimia Farma (Persero) Tbk (part of PT Bio Farma) · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Dec 2019, registered Jul 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this research was to investigate whether Furosemide 40 mg tablet manufactured by PT. Kimia Farma Tbk was bioequivalent to its reference drug and Lasix® 40 mg Tablet manufactured by PT. Aventis Pharma, Indonesia.

Read the detailed description

Twenty four healty volunteers were given a single dose of Furosemide 40 mg Tablet or Lasix® 40 mg Tablet with 240 mL of water beneath fasting condition. Then the blood samples for Furosemide were drawn and analyzed using UPLC. All subjects sample plasma were analyzed for pharmacokinetic evaluation

02

Conditions studied

  • Drug Use

Keywords

  • bioequivalence
  • furosemide
  • Indonesian healthy volunteers
03

In context

Lead sponsor

PT. Kimia Farma (Persero) Tbk is the lead sponsor of 4 studies on the registry; none are open to participants now.

First submitted after PT. Kimia Farma (Persero) Tbk became part of PT Bio Farma.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have read the subject information and signed documents
  • age 18 - 55 years
  • between 18-25 kg/m2
  • have a normal
  • blood pressure within normal range (systolic 90-120 mmHg and diastolic 60-80 mmHg)
  • heart rate within normal range (60-100 bpm)
  • with absence of significant disease or abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening
  • acceptance to use protection (condom) during intercourse with their spouse throughout the study

Exclusion criteria

Exclusion Criteria:

  • those who are pregnant and/or nursing women
  • those with a history of to furosemide, or other diuretics or other ingredients in the drugs or a history of serious allergic reaction to any drug, a significant allergic disease, or allergic reaction
  • those with a history or presence of medical condition which might significantly influence the pharmacokinetic of the study drug, e.g. chronic gastrointestinal disease, diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or cardiovascular disease.
  • those with a history or presence of any coagulation disorder or hematology abnormalities
  • those who are using any medication (prescription or non-prescription drug, food supplement, herbal medicine), particularly the medication known to affect the pharmacokinetic of the study drug, within one week prior to the drug administration day
  • those who have participated in any clinical study within 3 months prior to the study (\< 90 days)
  • those who have donated or lost 300 ml (or more) of blood within 3 months prior to the study
  • those who smoke more than 10 cigarettes a day
  • those who are positive to , , and tests (to be kept confidential)
  • those with a history of drug or alcohol abuse within 12 months prior to screening for this study
  • those who are unlikely to comply with the protocol, e.g uncooperative attitude, inability to return for follow up visits, poor venous access
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Furosemide 40 mg tablet

    volunteers received Furosemide 40 mg tablet with 240 mL of water

    Drug: Furosemide 40 mg

  • Active comparator
    Lasix® 40 mg Tablet

    volunteers received Lasix® 40 mg tablet with 240 mL of water

    Drug: Lasix® 40 mg Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric Mean Ratio of Maximum Concentration

    The ratio between test drug and reference drug

    Time frame: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration

  2. Geometric Mean Ratio of Area Under Curve

    The ratio between test drug and reference drug

    Time frame: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration

Secondary outcomes

  1. Pharmacokinetics Parameter

    Maximum plasma concentration

    Time frame: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration

  2. Pharmacokinetics Parameter

    Area Under Curve from 0 to 24 hours

    Time frame: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration

07

Results

Posted Nov 2, 2023

Participant flow

24 healthy volunteers were recruited from one research

1st Intervention
Participant flow — 1st Intervention
MilestoneTest Drug First, Then Reference DrugReference Drug First, Then Test Drug
Started1212
Completed1212
Not completed00
Washout Periods >= One Week
Participant flow — Washout Periods >= One Week
MilestoneTest Drug First, Then Reference DrugReference Drug First, Then Test Drug
Started1212
Completed1212
Not completed00
2nd Intervention
Participant flow — 2nd Intervention
MilestoneTest Drug First, Then Reference DrugReference Drug First, Then Test Drug
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryGeometric Mean Ratio of Maximum Concentration

The ratio between test drug and reference drug

Time frame:
before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration
Reported as:
Geometric mean · percentage
Geometric Mean Ratio of Maximum Concentration
percentageFurosemide 40 mg Tablet
Geometric Mean Ratio of Maximum Concentration104.51 (90.81 to 120.29)
PrimaryGeometric Mean Ratio of Area Under Curve

The ratio between test drug and reference drug

Time frame:
before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration
Reported as:
Geometric mean · percentage
Geometric Mean Ratio of Area Under Curve
percentageFurosemide 40 mg Tablet
Geometric Mean Ratio of Area Under Curve101.79 (95.08 to 108.98)
SecondaryPharmacokinetics Parameter

Maximum plasma concentration

Time frame:
before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration
Reported as:
Mean · ng/mL
Pharmacokinetics Parameter
ng/mLFurosemide 40 mg TabletLasix® 40 mg Tablet
Pharmacokinetics Parameter1893.09 ± 479.621907.32 ± 707.72
SecondaryPharmacokinetics Parameter

Area Under Curve from 0 to 24 hours

Time frame:
before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration
Reported as:
Mean · ng*h/mL
Pharmacokinetics Parameter
ng*h/mLFurosemide 40 mg TabletLasix® 40 mg Tablet
Pharmacokinetics Parameter4938.79 ± 1110.924921.94 ± 1279.14

Adverse events

Collected over before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Furosemide 40 mg Tablet0/24 (0%)0/24 (0%)5/24 (20.8%)
Lasix® 40 mg Tablet0/24 (0%)0/24 (0%)5/24 (20.8%)
Most frequent other events
Most frequent other events
EventFurosemide 40 mg TabletLasix® 40 mg Tablet
HeadacheNervous system disorders3/242/24
PolyuriaGastrointestinal disorders1/242/24
Frequent urinationGastrointestinal disorders2/241/24

Baseline characteristics

24 healthy volunteers

Age, Categorical
Age, Categorical(Participants)Total Number of Participants
<=18 years0
Between 18 and 65 years24
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Total Number of Participants
Female8
Male16
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Total Number of Participants
08

Study locations

1 site
  • PT Pharma Metric Labs
    Jakarta Pusat, DKI Jakarta 10520, Indonesia
09

References and documents

Publications

  • Chow SC. Bioavailability and Bioequivalence in Drug Development. Wiley Interdiscip Rev Comput Stat. 2014;6(4):304-312. doi: 10.1002/wics.1310. PubMed 25215170 ↗
  • Oh SW, Han SY. Loop Diuretics in Clinical Practice. Electrolyte Blood Press. 2015 Jun;13(1):17-21. doi: 10.5049/EBP.2015.13.1.17. Epub 2015 Jun 30. PubMed 26240596 ↗
  • Najib N, Idkaidek N, Beshtawi M, Bader M, Admour I, Alam SM, Zaman Q, Dham R. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers. Biopharm Drug Dispos. 2003 Sep;24(6):245-9. doi: 10.1002/bdd.361. PubMed 12973821 ↗
  • Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol. 2003 Jan;284(1):F11-21. doi: 10.1152/ajprenal.00119.2002. PubMed 12473535 ↗
  • Brater DC. Diuretic therapy. N Engl J Med. 1998 Aug 6;339(6):387-95. doi: 10.1056/NEJM199808063390607. No abstract available. PubMed 9691107 ↗
  • Sica DA. Diuretic use in renal disease. Nat Rev Nephrol. 2011 Dec 20;8(2):100-9. doi: 10.1038/nrneph.2011.175. PubMed 22183505 ↗
  • Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokinet. 1990 May;18(5):381-408. doi: 10.2165/00003088-199018050-00004. PubMed 2185908 ↗
  • Midha KK, McKay G. Bioequivalence; its history, practice, and future. AAPS J. 2009 Dec;11(4):664-70. doi: 10.1208/s12248-009-9142-z. Epub 2009 Oct 6. No abstract available. PubMed 19806461 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jan 2020, 1 month.

Results were first posted in Nov 2023, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2021
First posted
Jul 29, 2021
StartActual
Dec 13, 2019
Primary completionActual
Jan 17, 2020
CompletionActual
Jan 29, 2020
Results first posted
Nov 2, 2023
Last update
Nov 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04982874
Collaborators
PT Pharma Metric Labs
Responsible party
Sponsor
First posted
Jul 29, 2021
Start date
Dec 13, 2019
Primary completion
Jan 17, 2020
Completion
Jan 29, 2020
Results posted
Nov 2, 2023
Last update
Nov 2, 2023

Study contacts

Frans D Suyatna
principal investigator · PT Pharma Metric Labs
I Gusti Putu Bagus Diana Virgo
study director · PT Pharma Metric Labs

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide

Start the discussion